Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib + Erlotinib in Recurrent/Metastatic NSCLC
NCT01471964Phase 2Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- Oct 2011
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alisertib in non-small cell lung cancer (NSCLC), sponsored by Fox Chase Cancer Center. Started Oct 2011; status: terminated.
02
Drugs
alisertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01471964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01471964.